Menopause Supplements Are Growing Into a Real Science
The women’s health supplement market is on track to grow from $57.4 billion in 2024 to $77.4 billion by 2030, a compound annual growth rate of about 5.25%. The engine behind that growth is women in and around menopause who are no longer satisfied with generic multivitamins. They are looking for specific ingredient combinations matched to their biology at a specific life stage.
The Foundation: D3 Plus K2, Magnesium Glycinate, Omega-3
After menopause, declining estrogen accelerates the rate at which calcium leaves bone tissue. Vitamin D3 supports calcium absorption in the small intestine. K2 directs that absorbed calcium into bone rather than into arterial walls, where it can cause calcification. The pairing of these two nutrients is one of the most clinically established approaches for managing bone density loss after menopause.
Magnesium glycinate is a chelated form of magnesium that absorbs well and sits easily on the digestive system. Among the many forms of magnesium available, it is the one most consistently recommended for menopause-related sleep disturbances, muscle tension, and mood fluctuations. Magnesium participates in more than 300 enzymatic reactions, and deficiency shows up quickly as fatigue and disrupted sleep.
Omega-3 fatty acids address the cardiovascular risk shift that comes with menopause. Before menopause, women have substantially lower rates of cardiovascular disease than men of the same age. After menopause, that gap narrows. Supplementation with EPA and DHA-rich omega-3 has accumulated good evidence for lowering triglycerides and reducing vascular inflammation.
Collagen has also found a permanent spot in the menopause supplement category. The standard dose supported by clinical research is 10 grams per day for 8 to 12 weeks, with measurable improvements in skin elasticity and hydration. Because estrogen also regulates collagen synthesis, post-menopausal women lose collagen in skin and joints at a faster rate than before.
The Emerging Layer: NAD+ Precursors, Spermidine, Urolithin A, Polyphenols
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme central to cellular energy production and DNA repair. Its levels drop with age, and the decline is particularly pronounced after menopause. NMN and NR are both NAD+ precursors with early clinical data suggesting improvements in cellular energy output and mitochondrial function when supplemented.
Spermidine is a polyamine found in wheat germ and legumes that triggers autophagy, the cellular process by which damaged components are recycled and cleared. Austrian research has linked spermidine supplementation to improvements in cognitive function. Urolithin A, derived from pomegranates and berries, promotes mitochondrial autophagy and has shown clinical benefits for muscle endurance in trials published by Amazentis. Notably, the body’s ability to produce urolithin A from dietary sources varies enormously from person to person, which makes direct supplementation meaningful for many.
Polyphenols including resveratrol and fisetin are drawing attention for their potential to clear senescent cells and reduce oxidative stress, though large-scale trials specifically in menopausal women are still limited.
The data and the consumer behavior are moving in the same direction. Menopause is increasingly understood not as a deficiency state but as a transition point where optimization is possible. The question is no longer just what to take, but in what combination, and when to start.